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Background: To evaluate the feasibility of image-guided radiotherapy based on helical Tomotherapy to spare the
contralateral parotid gland in head and neck cancer patients with unilateral or no neck node metastases.
Methods: A retrospective review of 52 patients undergoing radiotherapy for head and neck cancers with image
guidance based on daily megavoltage CT imaging with helical tomotherapy was performed.
Results: Mean contralateral parotid dose and the volume of the contralateral parotid receiving 40 Gy or more were
compared between radiotherapy plans with significant constraint (SC) of less than 20 Gy on parotid dose (23
patients) and the conventional constraint (CC) of 26 Gy (29 patients). All patients had PTV coverage of at least 95%
to the contralateral elective neck nodes. Mean contralateral parotid dose was, respectively, 14.1 Gy and 24.7 Gy for
the SC and CC plans (p< 0.0001). The volume of contralateral parotid receiving 40 Gy or more was respectively
5.3% and 18.2% (p< 0.0001)
Conclusion: Tomotherapy for head and neck cancer minimized radiotherapy dose to the contralateral parotid
gland in patients undergoing elective node irradiation without sacrificing target coverage.
Keywords: Head and neck cancer, Tomotherapy, Parotid sparingBackground
Xerostomia remains one of the most common sequelae
of head and neck cancer radiotherapy because of exces-
sive radiation to the parotid glands [1-3]. Radiotherapy
induces apoptosis of the acinar glands leading to
decreased salivary production and decreases patient’s
quality of life [4,5]. The severity of dry mouth is propor-
tional to the radiation dose delivered to the parotid
glands [6]. Conventional radiotherapy with two lateral
fields leads to significant saliva reduction because of its
inability to spare the parotid glands from the radiation
fields. Introduction of intensity-modulated radiotherapy
(IMRT) leads to significant sparing of the parotid glands
in patients with clinically negative neck nodes because* Correspondence: NamPhong.Nguyen@yahoo.com
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reproduction in any medium, provided the orof rapid dose fall of from the target volume [7,8]. Mean
dose to the parotid gland is usually kept at 26 Gy or less
because of the observed recovery of saliva production
from the parotid gland with mean radiation doses up to
26 Gy [9]. However, in patients undergoing concurrent
chemoradiation, damage to the parotid gland may occur
with a lower dose because of the radiosensization effect
of chemotherapy [10]. Thus, minimizing radiation dose
to the parotid gland remains one of the challenges for
radiotherapy of head and neck cancer. Avoidance of
contralateral neck irradiation is one of the most effective
means of sparing the contralateral parotid gland from
radiation [11]. However, in patients with large tumors
(T3-T4), clinically positive neck nodes, or tumors affect-
ing an anatomic location with rich lymphatic drainage,
elective nodal irradiation (ENI) of the contralateral neck
is essential in optimizing regional control in the contra-
lateral neck [12]. In patients with unilateral cervicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not spared from radiation because of the risk of under-
dosing level II lymph node and to prevent recurrence in
the peri-parotid lymph node [13,14]. By sacrificing the
ipsilateral parotid gland and purposely under-dosing the
contralateral level II lymph nodes, significant sparing of
the contralateral parotid gland may be achieved with ad-
equate local control [14]. Ideally a radiotherapy tech-
nique that can achieve adequate coverage of the regional
lymph nodes at risk while minimizing contralateral par-
otid gland irradiation will lead to significant improve-
ment in patients’ quality of life as well as effective
regional control in the neck. Image-guided radiotherapy
(IGRT) has been recently introduced to decrease normal
tissue toxicity because of the rapid dose fall off com-
pared to IMRT [15]. Helical Tomotherapy is an image-
guided radiotherapy technique incorporating daily mega-
volt (MV) computed tomography (CT) planning and dy-
namic rotational IMRT [16]. Effectiveness of
Tomotherapy-based IGRT has been proven to be super-
ior to conventional IMRT for larynx and pharyngeal
muscles sparing in patients with non-laryngeal and -
hypopharyngeal cancers even in the presence of neck
node metastases [17]. We investigate in this report the
feasibility of Tomotherapy to reduce parotid gland ir-
radiation in head and neck cancer patients undergoing
elective neck node irradiation.
Methods
The medical records of 52 patients undergoing radio-
therapy for head and neck cancer at the University of
Arizona Radiation Oncology Department from Decem-
ber 2007 to March 2010 were retrospectively reviewed
following institutional review board (IRB) approval.
Patients with ipsilateral or bilateral clinical N0 neck re-
ceiving bilateral neck irradiation were selected for this
study. Patients who underwent unilateral neck irradi-
ation or presented with bilateral neck nodes metastases
at diagnosis were excluded because of the high recur-
rence risk associated with under-dosing level II and peri-
parotid lymph nodes [13,14] . All patients were treated
with the whole field (WF) IGRT technique on a helical
Tomotherapy (Hi-Art TomotherapyR) unit by a single
radiation oncologist with the same radiotherapy tech-
nique. Prior to treatment, each patient was simulated in
the supine position with a head and neck aquaplast
mask for treatment immobilization. A computed tomog-
raphy (CT) scan with and without intravenous (IV) con-
trast for treatment planning was performed in the
treatment position. The head and neck areas from the
vertex to the mid thorax were scanned with a slice thick-
ness of 3 mm. CT scan with IV contrast was employed
to outline the tumor and grossly enlarged cervical lymph
nodes for target volume delineation. Radiotherapyplanning was performed on the non-contrast CT scan to
avoid possible interference of contrast density on calcu-
lations radiotherapy isodose distributions. Diagnostic
positron emission tomography (PET)-CT scan planning
for tumor imaging was also incorporated with CT plan-
ning for target volume delineation whenever available. A
0.5 cm bolus material was placed on any area of the skin
involved by the tumor and on any palpable cervical
lymph nodes. Normal organs at risk for complication
were outlined for treatment planning (spinal cord, brain
stem, bilateral cochlea, mandible, parotid glands, larynx,
pharyngeal muscles, bilateral eyes, and oral cavity). Radi-
ation therapy dose was similar for all patients with the
integrated boost technique to decrease treatment
toxicity.
The tumor and grossly enlarged lymph nodes (GTV1)
on CT scan with a margin of 5 mm to 1 cm depending
on anatomic location (PTV1) were treated to 70 Gy in
35 fractions (2 Gy/fraction). The area at high risk-PTV2
(at least 1 cm around PTV1 if PTV1 was located in the
soft tissues with no anatomic barriers such as fatty tis-
sues or muscles) was treated to 63 Gy in 35 fractions
(1.8 Gy/fraction). If PTV1 was located adjacent to a
bony structure which constituted a natural barrier to
tumor spread and if there was no bony invasion
observed on CT scan, no additional dose level will be
added. In that specific case, PTV1 became PTV2. We
added PTV2 because of our earlier experience with the
IMRT technique when the target volume could not be
visualized to avoid marginal miss. The low risk -PTV3
or elective nodal irradiation (subclinical regional lymph
nodes with 5 mm margins) for tumor spread was treated
56 Gy in 35 fractions (1.6 Gy/fraction).
Minimal targetcoverage was 95% of the prescribed
dose for all targets with at least 99% of the prescribed
dose delivered to gross tumor and involved cervical
lymph nodes. The lymph nodes in the ipsilateral neck
including the retropharyngeal lymph nodes were treated
to the base of skull if there was any cervical lymph node
enlargement (or PET-positive lymph nodes). Contralat-
eral uninvolved lymph nodes were treated prophylactic-
ally with the C1 vertebrae as the superior border of the
treatment field. Mean dose to the contralateral parotid
was kept below 26 Gy (conventional constraint) if there
was no cervical lymph node enlargement in the histor-
ical control group (29 patients). However, if this parotid
dose was not achievable, the lowest mean parotid dose
that allowed target coverage was accepted. Mean dose to
contralateral parotid was kept below 20 Gy (significant
constraint) for the study group (23 patients) consistent
with the quantitative analyses of normal tissue effects in
clinic recommendation (QUANTEC) [18]. These 23
patients were treated after publication of the QUANTEC
recommendations. In patients with unilateral neck
Table 1 Patient characteristics
Study Historical
control
Total
Patient No 23 29 52
Age
Median 66 60 63
Range 25–92 26–90 25–92
Sex
Male 21 28 49
Female 2 1 3
Squamous histology 22 30 52
Tumor sites
Oropharynx 5 10 15
Oral cavity 7 8 15
Parotid (primary or metastates) 3 1 4
Larynx 4 6 10
Hypopharynx 2 2 4
Unknown 1 2 3
Nasopharynx 1 0 1
Stages
I 0 2 2
II 2 1 3
III 9 12 21
IVA 6 10 16
IVB 3 4 7
IVC 2 0 2
Recurrence 1 0 1
T stages
Tx 1 2 3
T1 1 4 5
T2 13 10 23
T3 3 8 11
T4 4 5 9
Recurrence 1 0 1
Neck nodes
N0 3 8 11
N1 13 9 22
N2 4 10 14
N3 2 2 4
Recurrence 1 0 1
Treatement
Radiotherapy alone 5 5 10
Chemoradiation 18 24 42
Study: Mean parotid dose constraints less than 20 Gray; Control: Mean parotid
dose constraints 26 Gy.
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to avoid any marginal miss because of the close proxim-
ity of the parotid gland to the jugular digastric lymph
node. There was also no attempt to spare the subman-
dibular glands from radiation. Dose constraints for other
normal organs at risk (OAR) for complications were:
spinal cord (45 Gy), brain stem (50 Gy), optic chiasm
(45 Gy), mandible (70 Gy to less than 30% of the man-
dible). Doses to larynx and pharyngeal muscles for non-
laryngeal and - hypopharyngeal cancers were kept be-
tween 20–40 Gy if feasible. Statistical analysis was per-
formed with the Welch’s t test. A difference of <0.05
was considered statistically significant.
We identified 52 patients with invasive squamous cell
carcinoma of the head and neck treated at the University
of Arizona Radiation Oncology departmentfrom 2007 to
2010. Median age at diagnosis was 63 years-old (range:
25–92 years old). There were 49 males and 3 females.
Disease sites were respectively: oropharynx (15), oral
cavity (15), larynx (10), hypopharynx (4), parotid (4), un-
known (3), and nasopharynx (1). There were two stage I,
three stage II, 21 stage III, 16 stage IVA, 7 stage IVB,
two stage IVC, and one recurrence. 41 patients had uni-
lateral neck metastases and 11 patients had no neck
nodes. Treatment consisted of: radiotherapy alone (10),
and concurrent chemoradiation (42). Table 1 sum-
marizes the patient characteristics. Table 2 summarizes
patient clinical outcome in both groups. Two patients in
the study group died during treatment from aspiration
pneumonia (1) and disease progression (1). No patient
in either groups had recurrences in the parotid area. As
this is a retrospective study, there was no clinical infor-
mation on the impact of parotid sparing on the severity
of xerostomia.
Results
Mean contralateral parotid dose was, respectively
14.1 Gy (range: 6.5 Gy to 19.9 Gy) and 24.7 Gy (range:
20.1 Gy to 34 Gy) for the study group (SC) and historical
control group (CC) [95% CI: 8.5 to 12.5] (p< 0.0001).
The volume of the contralateral parotid receiving 40 Gy
was respectively, 5.3% (range: 0 to 14%) and 18.2%
(range: 3% to 35%) [95% CI: 9.5 to 16.1] (p< 0.0001).
Figures 1 and 2 illustrate respectively the mean dose and
volume of the contralateral parotid gland receiving
40 Gy. There was no significant difference in PTV cover-
age between the two groups. Mean PTV coverage for the
historical control group and study group was respect-
ively 96.1% (range: 95% to 98%) and 96.8% (range: 95%
to 98%). Figure 3 illustrates the effectiveness of
Tomotherapy to decrease radiation dose to both parotids
in a patient with locally advanced laryngeal cancer and
negative neck nodes. We also assessed the mean bilateral
parotid dose in both groups even though we did not put
Table 2 Clinical outcome following image-guided
radiotherapy of the control group and the study group
Study (23) Historical control (29)
Lost for follow-up 1 0
Follow-up (months)
Median 20 31
Range 1–39 1–48
Alive 14 (63.6%) 21 (72.4%)
Local recurrences 5 (22.7%) 5 (17.2%)
Regional recurrences 2 (9%) 2 (6.9%)
Distant metastases 2 (9%) 4 (13.8%)
Death during treatment 2 (1 aspiration
pneumonia, 1
disease progression)
0
Control Sparing
0.
05
0.
10
0.
15
0.
20
0.
25
0.
30
V40
Figure 2 Volume of contralateral parotid gland receiving 40 Gy
in head and neck cancer patients undergoing image-guided
radiotherapy with conventional (historical control group) and
significant constraint (study group) on parotid dose.
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like to verify that Tomotherapy can selectively spare the
contralateral parotid gland because of the beams
optimization without excessively increasing dose to the
ipsilateral parotid gland. For this analysis, patients with
primary tumors located in the parotid gland were
excluded because of the high dose to the tumor (70 Gy).
Mean bilateral parotid dose (right and left) was respect-
ively 28.2 Gy and 30.8 Gy for the study group and con-
trol group [95% CI: -1.7 to 7] (p= 0.2). We also
investigated whether the parotid sparing efficacy of
Tomotherapy was not due to excessive dose to the sur-
rounding normal structures such as the spinal cord and
mandible.Control Sparing
15
20
25
30
35
Mean
Figure 1 Mean contralateral parotid dose in head and neck
cancer patients undergoing image-guided radiotherapy with
conventional (historical control group) and significant
constraint (study group) on parotid dose.We compared the maximum spinal cord and mean
mandibular dose between patients with oropharyngeal,
oral cavity, and laryngeal-hypopharyngeal cancer in the
study group and historical control group. Tumors of the
larynx and hypopharynx were grouped together because
of the small number of patients and their close anatomic
location. There were no significant difference in spinal
cord or mandibular dose. Table 3 summarizes spinal
cord and mandibular dose of the study and historical
control group. We also raised the question whether
Tomotherapy can effectively spare both parotid glands
in the absence of cervical lymph node. Eleven patients
did not have cervical lymph nodes involvement, three in
the study group and eight in the control group. Mean
total parotid dose was respectively 15.5 Gy and 26.2 Gy
for the study group and the control group [95% CI: 2.3
to 19.1] (p= 0.02)
Discussion
To our knowledge, the present work represents the first
study attempting to reduce the dose to the parotid in
patients undergoing elective neck node radiotherapy for
head and neck cancer employing helical tomotherapy
with IGRT. All patients in our study were treated with
Tomotherapy. Tomotherapy provides significant dose
reduction to the parotid gland without compromise of
target volume dose. In an effort to reduce parotid dose,
our main concern was to treat the regional neck nodes
at risk for subclinical disease effectively to 56 Gy in 35
fractions. We discovered in a previous study that
Figure 3 Illustration of the effectiveness of Tomotherapy to decrease radiation dose to both parotids in a patient with locally
advanced laryngeal cancer and negative neck nodes on PET-CT scan (T3N0M0). The tumor bed and bilateral levels II-IV neck nodes were
treated to 70 Gy (red) and 56 Gy (yellow) respectively. Despite the close proximity of the parotid glands to the 56 Gy isodose line, mean parotid
dose was 11.2 Gy for the right and 12.7 Gy for the left.
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ing laryngeal and pharyngeal dose compared to conven-
tional IMRT in patients with head and neck cancer [17].
Thus, our initial goal was to achieve a modest reduction
of mean parotid dose below 20 Gy with Tomotherapy
while covering the elective neck PTV with at least 95%
of the prescribed dose. Our parotid dose reduction was
based on a review of the literature of normal tissue tox-
icity following head and neck radiotherapy: QUANTEC
recommends a mean parotid dose of 20 Gy or less if
only one parotid gland can be spared from radiotherapy
[18]. As we acquired more experience, we gradually
developed a technique that provided significant reduc-
tion of parotid dose regardless of the cancer anatomic
site. In selected patients, a mean parotid dose of 10 Gy
or less may be achieved. This is particularly important in
patients who underwent concurrent chemoradiation for
oral cavity and oropharyngeal tumors with unilateral
lymph nodes metastases when the ipsilateral parotid,
submandibular, and minor salivary glands received high
radiation dose. These patients remained at high risk forsevere xerostomia following head and neck radiotherapy
because of the tumor location and disease extent. Pre-
serving one parotid gland from excessive radiotherapy
may improve patient quality of life without compromis-
ing local control.
Many studies have looked into relationships between
parotid radiation dose and degree of xerostomia severity.
Additionally, other studies have correlated the mean par-
otid dose with the subsequent reduction of salivary flow.
Therefore, we have reviewed studies in which dose-
volume histograms were performed with treatment plan-
ning head and neck CT scan reporting the mean parotid
dose and the associated risk of xerostomia. Eisbruch
et al. [9] reported that maintaining mean parotid dose
below 26 Gy lead to recovery of stimulated salivary flow
at one year following head and neck radiotherapy. Mun-
ter et al. [19] also corroborated that reducing mean par-
otid dose below 26 Gy with IMRT significantly preserved
salivary function. Chao et al. [20] reported a direct cor-
relation between the mean parotid dose and the
decreased rate of stimulated salivary flow estimated to
Table 3 Maximum spinal cord dose and mean mandibular
dose (Gray) in the study group and historical control
group for oropharyngeal, oral cavity, and laryngeal-
hypopharyngeal cancers
Site Spinal cord Mandibular
Study Control p value Study Control p value
Oropharynx 35.2 39.3 0.1 39.2 44.9 0.4
Oral cavity 33.6 36.9 0.1 55.4 57.2 0.4
Larynx and hypopharynx 34.2 36.1 0.5 30 31.8 0.8
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studies have suggested alternated parameters of parotid
dose levels for the development of xerostomia following
head and neck radiotherapy. Bussels et al. [3] reported a
50% loss of salivary function with mean parotid dose of
22.5 Gy at 7 months following head and neck cancer
IMRT. Roesink et al. [6] reported increased risk of devel-
oping severe xerostomia with mean parotid dose of
39 Gy. Saarilahti et al. [21] reported minimal reduction
of stimulated salivary flow with mean parotid dose of
18 Gy or less and marked decreased of saliva production
with parotid dose between 20–30 Gy. Table 4 sum-
marizes mean parotid dose reported in the literature and
radiotherapy effect on salivary gland production.
The discrepancies between these studies may be due
to many factors such as parotid size, heterogeneity of
IMRT dose distribution within the parotid glands, inclu-
sion of patients treated with chemoradiation which
increased radiosensibility of the salivary glands, and
inter-patient variability in loss of salivary function. In
patients who underwent ipsilateral neck irradiation for
well lateralized oral cavity or oropharyngeal tumors, the
mean dose to the contralateral parotid gland was 4.7 Gy
[11]. The low contralateral parotid dose decreased xeros-
tomia severity and improved patient quality of life.
Ortholan et al. [22] also corroborated that reduction of
contralateral parotid gland dose lead to recovery ofTable 4 Mean parotid dose in relation to reduction of salivary
planning head and neck computed tomography scans
Study Patient No Technique to assess s
Teshima et al. [1] 20 Saxon test
Bussels et al. [3] 16 Scintigraphy
Roesink et al. [6] 108 Suction cup
Eisbruch et al. [9] 88 Suction cup
Cerezo et al. [11] 16 Spitting cup
Munter et al. [19] 18 Scintigraphy
Chao et al. [20] 41 Spitting cup
Saarilahti et al. [21] 17 Spitting cup
Gy: Gray; NS: not specified.salivary function. If the volume of the contralateral par-
otid gland receiving 40 Gy (V40) was kept below 33%,
complete salivary production recovered after two years.
It was postulated that sparing of the contralateral par-
otid gland allowed it to compensate for the low salivary
production of the ipsilateral gland. The feasibility of this
approach has been demonstrated in improving patient
quality of life [23]. Thus, because a large proportion of
the study population received concurrent chemotherapy
for locally advanced head and neck cancer which had an
additive effect on salivary flow, we devised a new policy
to preserve salivary gland function by reducing mean
contralateral parotid dose with Tomotherapy.
Helical Tomotherapy has been proven to deliver a
sharper dose gradient compared to conventional IMRT,
thus reducing radiation dose to the parotids without
compromising target coverage [13,24]. Mean and V40
contralateral parotid dose was respectively 14.1 Gy and
24.7 Gy and 5.5% and 18.2% for the study and historical
control populations (p< 0.0001). Even though we lack
information on salivary flow following radiotherapy with
parotid sparing Tomotherapy, our study demonstrates
the feasibility of this new technique to potentially im-
prove patient quality of life because of low radiation
dose to the contralateral parotid gland. In a pilot study,
Voordeckers et al. [25] reported the feasibility of
Tomotherapy to conserve salivary function if 46% of the
unilateral parotid volume received a dose less than
60 Gy. Maes et al. [26] demonstrated that salivary gland
function may be preserved if the contralateral parotid
gland received 20 Gy or less. Using scintigraphy to
measure salivary flow following radiotherapy with 3-
dimensional (3-D) conformal radiotherapy, 70% of the
parotid function may recover six months following treat-
ment. Thus, as the study mean parotid dose was 14.1 Gy
and only a minimal volume of the parotid gland received
more than 40 Gy (5.5%), we can expect that our patients
may benefit from significant xerostomia reduction. Weflow in studies with dose-volume histogram based on
alivary flow Mean parotid dose Evaluation time
30 Gy NS
22.5 Gy 7 months
39 Gy 12 months
26 Gy 12 months
4.7 Gy (contralateral
unirradiated parotid)
12 months
26 Gy 6 months
30 Gy 6 months
25.5 Gy 12 months
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promise target coverage as there was no difference in
PTV coverage between the two groups. In addition, daily
megavoltage computed tomography (MVCT) imaging
for patient set up allows for on-line correction of patient
positioning variation and insures accurate dose delivery
and sparing of the parotid glands [27]. We demonstrate
that reduction of contralateral parotid dose was achieved
without any increase of radiation dose to the ipsilateral
parotid gland, spinal cord, or mandible. In patients with
no cervical lymph nodes metastases, mean parotid dose
in the study group was significantly lower than the his-
torical control group. Even though the patient number
with N0 node was small, we postulate that Tomotherapy
provides optimal sparing of the parotid gland while pre-
serving target coverage because of the high number of
beamlets associated with dynamic rotational IMRT and
sharp dose gradient [16]. Our clinical study also con-
firmed the dosimetric experience of other investigators
about the potential of Tomotherapy for improving target
coverage while minimizing radiation dose to the normal
tissues in head and neck cancer patients. Lee et al. [28]
compared the dose volume histogram (DVH), conform-
ity index (CI), homogeneity index (HGI) and minimal
dose to 1 cc (Dmin-1 cc) of 20 nasopharyngeal cancer
patients treated with Tomotherapy and re-planned with
step-and-shoot IMRT. Tomotherapy significantly
improved CI and HI of the PTV while significantly
reduced radiation dose to the other organs at risk for
complications. Mean dose to the parotid glands was 28%
less compared to IMRT. Jacob et al. [29] also corrobo-
rated the superiority of Tomotherapy in providing better
coverage to the target volume (higher minimum dose)
compared to RapidArc and dynamic IMRT. Parotid dose
was lowest with Tomotherapy. The improved thera-
peutic ratio of Tomotherapy was also reported in two
other dosimetric studies [30,31], thus arguing that
Tomotherapy may be best suited to reduce xerostomia
compared to other IMRT techniques if significant con-
straint was placed on parotid dose. The limitations of
the present study include the retrospective nature of the
study, the small number of patients, and the lack of in-
formation on salivary production before and after radio-
therapy. We also did not have information on the
impact of parotid sparing on the severity of xerostomia
and patient quality of life. Nevertherless, we hope that
our study will encourage other institutions to investigate
the potential of Tomotherapy to spare the parotid gland
from possible excessive morbidity of radiotherapy, thus
improving quality of life in cancer survivors.
Conclusion
Image-guided radiotherapy based on helical Tomother-
apy may provide significant reduction of radiation doseto the contralateral parotid gland for patients with head
and neck cancers without any compromise of target
coverage or excessive radiation to other normal struc-
tures. This innovative technique should be investigated
to assess if it can improve patient quality of life following
head and neck radiotherapy.
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